Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (DBCOND0080506)

Identifiers

Synonyms

Diffuse Large B-Cell Lymphoma (DLBCL), Nos / Diffuse large B-cell lymphoma NOS / Diffuse large B-cell lymphoma / Diffuse large B cell malignant lymphoma (morphologic abnormality) / Diffuse large B-cell lymphomas / Diffuse non-Hodgkin's lymphoma, large cell (disorder) / Lymphoma, Large B-Cell, Diffuse / Malignant lymphoma, large B-cell, diffuse (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Polatuzumab vedotin	A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma.	Cytochrome P450 3A4enzyme B-cell antigen receptor complex-associated protein beta chaintarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A5enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04113226	Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma	Lenalidomide Rituximab	treatment	2	recruiting
NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	Nivolumab Varlilumab	treatment	2	active_not_recruiting
NCT03984448	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	Beta-D-Glucose Cortisone Cyclophosphamide Doxorubicin Etoposide Prednisone Rituximab Sulfate ion Venetoclax Vincristine	treatment	2 / 3	active_not_recruiting
NCT04799275	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma	Azacitidine Cortisone Cyclophosphamide Doxorubicin Prednisone Rituximab Sulfate ion Vincristine	treatment	2 / 3	recruiting
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Beta-D-Glucose Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Glofitamab Polatuzumab vedotin Prednisone Rituximab	treatment	1	recruiting
NCT06238648	Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy	Epcoritamab	treatment	2	recruiting
NCT06486051	A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma	Cyclophosphamide Fludarabine	treatment	2	recruiting
NCT03850028	Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients	No drug interventions	diagnostic	Not Available	withdrawn
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	Acalabrutinib Axicabtagene ciloleucel Tyrosine	treatment	1 / 2	recruiting
NCT05908409	A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies	No drug interventions	treatment	1 / 2	recruiting
NCT03656835	Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma	No drug interventions	diagnostic	Not Available	recruiting
NCT06014762	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	Rimiducid	treatment	1	recruiting
NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Lenalidomide Mosunetuzumab Muromonab Polatuzumab vedotin	treatment	1	recruiting
NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Cyclophosphamide Durvalumab Fludarabine JCAR014	treatment	1	terminated
NCT03742258	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Cortisone Cyclophosphamide Doxorubicin Prednisone Rituximab Sulfate ion Vincristine	treatment	1	unknown_status
NCT05786989	Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma	Escitalopram Selinexor	treatment	4	recruiting
NCT05733650	Expanded Access Program for Epcoritamab	Epcoritamab	Not Available	Not Available	approved_for_marketing
NCT04205838	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma	Anakinra Axicabtagene ciloleucel Cyclophosphamide Fludarabine	prevention	2	recruiting